Influenza virus-like particle vaccines

Expert Review of Vaccines

Volumn 8, Issue 4, 2009, Pages 435-445

  Haynes, Joel R ^a  

^a LigoCyte Pharmaceuticals Inc   (United States)

Author keywords

Influenza vaccine; Virus like particle

Indexed keywords

GAG PROTEIN; HEMAGGLUTININ; INFLUENZA VACCINE; SIALIDASE; VIRUS ANTIGEN; HEMAGGLUTININ FUSOGENIC PEPTIDE, INFLUENZA VIRUS; M1 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; NA PROTEIN, INFLUENZA A VIRUS; VIROSOME VACCINE; VIRUS HEMAGGLUTININ; VIRUS PROTEIN;

HEMAGGLUTINATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOTYPING; REVIEW; VIRUS LIKE AGENT; VIRUS STRAIN; ANIMAL; CELL LINE; GENETICS; IMMUNOLOGY; INSECT;

ANIMALS; CELL LINE; GENE PRODUCTS, GAG; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INSECTS; NEURAMINIDASE; VACCINES, VIROSOME; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 65449144444     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.8     Document Type: Review

References (95)

1. Blutt SE, Warfield KL, Estes MK, Conner ME. Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity. J. Virol. 82(6), 3135-3138 (2008).
2. Antonis AF, Bruschke CJ, Rueda P et al. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 24(26), 5481-5490 (2006). (Pubitemid 43831379)
3. Yang C, Ye L, Compans RW. Protection against filovirus infection: virus-like particle vaccines. Expert. Rev. Vaccines 7(3), 333-344 (2008).
4. Elmowalid GA, Qiao M, Jeong SH et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl Acad. Sci. USA 104(20), 8427-8432 (2007). (Pubitemid 47175504)
5. Jeong SH, Qiao M, Nascimbeni M et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J. Virol. 78(13), 6995-7003 (2004). (Pubitemid 38781538)
6. Souza M, Costantini V, Azevedo MS, Saif LJ. A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine 25(50), 8448-8459 (2007). (Pubitemid 350137597)
7. Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J. Clin. Oncol. 25(20), 2975-2982 (2007). (Pubitemid 47123162)
8. Reisinger KS, Block SL, Lazcano-Ponce E etal. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr. Infect. Dis. J. 26(3), 201-209 (2007). (Pubitemid 46340765)
9. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 63(10), 1021-1051 (2003). (Pubitemid 36575466)
10. Guo L, Lu X, Kang SM et al. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology 313(2), 502-513 (2003). • Demonstrates that the incorporation of influenza hemagglutinin (HA) into lentivirus virus-like particles (VLPs) augments the immune response to the VLPs. This may be due to the receptor-binding properties of HA allowing for better VLP targeting to antigen-presenting cells. (Pubitemid 37040690)
11. Huckriede A, Bungener L, Stegmann T et al. The virosome concept for influenza vaccines. Vaccine 23(Suppl. 1), S26-S38 (2005). (Pubitemid 41019630)
12. Treanor J, Nolan C, O'Brien D et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24(3), 254-262 (2006). (Pubitemid 41790428)
13. Moser C, Amacker M, Kammer AR et al. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert. Rev. Vaccines 6(5), 711-721 (2007). (Pubitemid 47610491)
14. Scheiffele P, Rietveld A, Wilk T, Simons K. Influenza viruses select ordered lipid domains during budding from the plasma membrane. J. Biol. Chem. 274(4), 2038-2044 (1999). (Pubitemid 29061354)
15. Leser GP, Lamb RA. Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins. Virology 342(2), 215-227 (2005). (Pubitemid 41566654)
16. Takeda M, Leser GP, Russell CJ, Lamb RA. Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc. Natl Acad. Sci. USA 100(25), 14610-14617 (2003). (Pubitemid 37521285)
17. Barman S, Ali A, Hui EK, Adhikary L, Nayak DP. Transport of viral proteins to the apical membranes and interaction of matrix protein with glycoproteins in the assembly of influenza viruses. Virus Res. 77(1), 61-69 (2001). (Pubitemid 32622811)
18. Schmitt AP, Lamb RA. Influenza virus assembly and budding at the viral budozone. Adv. Virus Res. 64, 383-416 (2005).
19. Ali A, Avalos RT, Ponimaskin E, Nayak DP. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J. Virol. 74(18), 8709-8719 (2000). (Pubitemid 30666721)
20. Enami M, Enami K. Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the membrane association of the matrix protein. J. Virol. 70(10), 6653-6657 (1996). (Pubitemid 26307370)
21. Zhang J, Pekosz A, Lamb RA. Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins. J. Virol. 74(10), 4634-4644 (2000). (Pubitemid 30237888)
22. Jin H, Leser GP, Zhang J, Lamb RA. Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J. 16(6), 1236-1247 (1997). (Pubitemid 27136090)
23. McCown MF, Pekosz A. The influenza A virus M2 cytoplasmic tail is required for infectious vitus production and efficient genome packaging. J. Virol. 79(6), 3595-3605 (2005). (Pubitemid 40327948)
24. McCown MF, Pekosz A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J. Virol. 80(16), 8178-8189 (2006). (Pubitemid 44182318)
25. Chen BJ, Leser GP, Jackson D, Lamb RA. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J. Virol. 82(20), 10059-10070 (2008).
26. Gomez-Puertas P, Albo C, Perez-Pastrana E, Vivo A, Portela A. Influenza virus matrix protein is the major driving force in virus budding. J. Virol. 74(24), 11538-11547 (2000). (Pubitemid 32222302)
27. Demirov DG, Freed EO. Retrovirus budding. Virus Res, 106(2), 87-102 (2004). (Pubitemid 39582739)
28. Gheysen D, Jacobs E, de Foresta F et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59(1), 103-112 (1989). (Pubitemid 19248562)
29. Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251(1), 1-15 (1998). (Pubitemid 28527713)
30. Harty RN, Paragas J, Sudol M, Palese P. A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J. Virol. 73(4), 2921-2929 (1999). (Pubitemid 29135680)
31. Justice PA, Sun W, Li Y et al. Membrane vesiculation function and exocytosis of wild-type and mutant matrix proteins of vesicular stomatitis virus. J Virol. 69(5), 3156-3160 (1995).
32. Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc. Natl Acad. Sci. USA 97(25), 13871-13876 (2000).
33. Timmins J, Schoehn G, Ricard-Blum S et al. Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4. J. Mol. Biol. 326(2), 493-502 (2003). (Pubitemid 36279343)
34. Timmins J, Scianimanico S, Schoehn G, Weissenhorn W. Vesicular release of Ebola virus matrix protein VP40. Virology 283(1), 1-6 (2001). (Pubitemid 32911504)
35. Licata JM, Johnson RF, Han Z, Harty RN. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol. 78(14), 7344-7351 (2004). (Pubitemid 38915880)
36. Ciancanelli MJ, Basier CF. Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J. Virol. 80(24), 12070-12078 (2006). (Pubitemid 44904357)
37. Coronel EC, Murti KG, Takimoto T, Portner A. Human parainfluenza virus type 1 matrix and nucleoprotein genes transiently expressed in mammalian cells induce the release of virus-like particles containing nucleocapsid-like structures. J. Virol. 73(8), 7035-7038 (1999). (Pubitemid 29327890)
38. Schmitt AP, Leser GP, Morita E, Sundquist WI, Lamb RA. Evidence for a new viral late-domain core sequence, FPIV, necessary for budding of a paramyxovirus. J. Virol. 79(5), 2988-2997 (2005). (Pubitemid 40270578)
39. Schmitt AP, Leser GP, Waning DL, Lamb RA. Requirements for budding of paramyxovirus simian virus 5 virus-like particles. J. Virol. 76(8), 3952-3964 (2002). (Pubitemid 34250560)
40. Sugahara F, Uchiyama T, Watanabe H et al. Paramyxovirus Sendai virus-like particle formation by expression of multiple viral proteins and acceleration of its release by C protein. Virology 325(1), 1-10 (2004). (Pubitemid 38844764)
41. Chen BJ, Leser GP, Morita E, Lamb RA. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J. Virol. 81(13), 7111-7123 (2007). • Dispels the popular paradigm by showing that influenza HA and neuraminidase (NA) exhibit budding activity in mammalian cells originally attributed to M1. (Pubitemid 46986647)
42. Mena I, Vivo A, Perez E, Portela A. Rescue of a synthetic chloramphenicol acetyltransferase RNA into influenza virus-like particles obtained from recombinant plasmids. J. Virol. 70(8), 5016-5024 (1996). (Pubitemid 26240671)
43. Gomez-Puertas P, Mena I, Castillo M et al. Efficient formation of influenza virus-like particles: dependence on the expression levels of viral proteins. J. Gen. Virol. 80 (Pt 7), 1635-1645 (1999). (Pubitemid 29319854)
44. Neumann G, Watanabe T, Kawaoka Y. Plasmid-driven formation of influenza virus-like particles. J. Virol. 74(1), 547-551 (2000). (Pubitemid 30002939)
45. Watanabe T, Watanabe S, Neumann G, Kida H, Kawaoka Y. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J. Virol. 76(2), 767-773 (2002). (Pubitemid 34033374)
46. Neumann G, Watanabe T, Ito H et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl Acad. Sci. USA 96(16), 9345-9350 (1999). (Pubitemid 29374757)
47. Cox M. Progress on baculovirus-derived influenza vaccines. Curr. Opin. Mol. Ther. 10, 56-61 (2008).
48. Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 75(13), 6154-6165 (2001). • First demonstration of the formation of nontransducing, structural influenza VLPs in the insect cell/baculovirus-expression system. (Pubitemid 32553146)
49. Pushko P, Tumpey TM, Bu F et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23(50), 5751-5759 (2005). (Pubitemid 41668881)
50. Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25(19), 3871-3878 (2007). (Pubitemid 46589748)
51. Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 81(7), 3514-3524 (2007). (Pubitemid 46456660)
52. Matassov D, Cupo A, Galarza JM. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol. 20(3), 441-452 (2007). (Pubitemid 47585318)
53. Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3(1), E1501 (2008). • First demonstration of the protective efficacy of VLPs representing highly pathogenic avian influenza (H5N1).
54. Mahmood K, Bright RA, Mytle N et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26(42), 5393-5399 (2008).
55. Manie SN, de Breyne S, Vincent S, Gerlier D. Measles virus structural components are enriched into lipid raft microdomains: a potential cellular location for virus assembly. J. Virol. 74(1), 305-311 (2000). (Pubitemid 30002910)
56. Nguyen DH, Hildreth JE. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J. Virol. 74(7), 3264-3272 (2000). (Pubitemid 30143751)
57. Pickl WF, Pimentel-Muinos FX, Seed B. Lipid rafts and pseudotyping. J. Virol. 75(15), 7175-7183 (2001). (Pubitemid 32641605)
58. Briggs JA, Wilk T, Fuller SD. Do lipid rafts mediate virus assembly and pseudotyping? J. Gen. Virol. 84(Pt 4), 757-768 (2003). (Pubitemid 36432205)
59. Pike LJ. Lipid rafts: bringing order to chaos. J. Lipid Res. 44(4), 655-667 (2003). (Pubitemid 37279667)
60. Scheiffele P, Roth MG, Simons K. Interaction of influenza virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane domain. EMBO J. 16(18), 5501-5508 (1997). (Pubitemid 27399842)
61. Barman S, Adhikary L, Chakrabarti AK et al. Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding. J. Virol. 78(10), 5258-5269 (2004). (Pubitemid 38581477)
62. Leung K, Kim JO, Ganesh L et al. HIV-1 assembly: viral glycoproteins segregate quantally to lipid rafts that associate individually with HIV-1 capsids and virions. Cell Host Microbe 3(5), 285-292 (2008). • Demonstration of nonrandom targeting of two different viral envelope glycoproteins to lipid rafts.
63. Panchal RG, Ruthel G, Kenny TA et al. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc. Natl Acad. Sci. USA 100(26), 15936-15941 (2003). (Pubitemid 38021093)
64. Manes S, del Real G, Martinez AC. Pathogens: raft hijackers. Nat. Rev. Immunol. 3(7), 557-568 (2003).
65. Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in influenza virus particles. PLoS Pathog. 4(6), e1000085 (2008).
66. Szecsi J, Boson B, Johnsson P et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol. J. 3, 70 (2006). • First demonstration of the production of influenza-pseudotyped Gag VLPs. (Pubitemid 44401678)
67. Haynes JR, Dokken L, Wiley JA et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27(4), 530-541 (2009). • Demonstrates very potent protection protection against H5N1 in ferrets with an influenza-pseudotyped Gag VLP from insect cells.
68. Haffar O, Garrigues J, Travis B et al. Human immunodeficiency virus-like, nonreplicating, Gag-Env particles assemble in a recombinant vaccinia virus expression system. J. Virol. 64(6), 2653-2659 (1990).
69. Haynes JR, Cao SX, Rovinski B et al. Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines. AIDS Res. Hum. Retroviruses 7(1), 17-27 (1991).
70. Karacostas V, Nagashima K, Gonda MA, Moss B. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc. Natl Acad. Sci. USA 86(22), 8964-8967 (1989). (Pubitemid 20010346)
71. Rovinski B, Haynes JR, Cao SX et al. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS Vaccine. J. Virol. 66(7), 4003-4012 (1992).
72. Yamshchikov GV, Ritter GD, Vey M, Compans RW. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology 214(1), 50-58 (1995).
73. Rein A, McClure MR, Rice NR, Luftig RB, Schultz AM. Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus. Proc. Natl Acad. Sci. USA 83(19), 7246-7250 (1986). (Pubitemid 16000500)
74. Schultz AM, Rein A. Unmyristylated Moloney murine leukemia virus Pr65gag is excluded from virus assembly and maturation events. J. Virol. 63(5), 2370-2373 (1989). (Pubitemid 19107839)
75. Yu Z, Beer C, Koester M, Wirth M. Caveolin-1 interacts with the Gag precursor of murine leukaemia virus and modulates virus production. Virol. J. 3, 73 (2006). (Pubitemid 44449055)
76. McKay T, Patel M, Pickles RJ, Johnson LG, Olsen JC. Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther. 13(8), 715-724 (2006).
77. D'Aoust MA, Lavoie PO, Couture MM et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol. J. 6(9), 930-940 (2008).
78. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 18(1), 244-251 (2005). • First demonstration of the immunogenicity of M1-based influenza VLPs from insect cells. (Pubitemid 40586463)
79. Pushko P, Tumpey TM, Van Hoeven N et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25(21), 4283-4290 (2007). (Pubitemid 46646962)
80. Crevar CJ, Ross TM. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol. J. 5, 131 (2008).
81. Quan FS, Steinhauer D, Huang C et al. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26(26), 3352-3361 (2008).
82. Wang BZ, Quan FS, Kang SM et al. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J. Virol. 82(23), 11813-11823 (2008).
83. + T-cell response induced in trivalent inactivated vaccine recipients. J. Virol. 82(18), 9283-9287 (2008).
84. De Filette M, Fiers W, Martens W et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24(44-46), 6597-6601 (2006). (Pubitemid 46127431)
85. De Filette M, Min Jou W, Birkett A et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337(1), 149-161 (2005). (Pubitemid 40725448)
86. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W. A 'universal' human influenza A vaccine. Virus Res. 103(1-2), 173-176 (2004).
87. Lamb RA, Zebedee SL, Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40(3), 627-633 (1985). (Pubitemid 15076578)
88. Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 62(8), 2762-2772 (1988). (Pubitemid 18193871)
89. Zebedee SL, Richardson CD, Lamb RA. Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA. J. Virol. 56(2), 502-511 (1985). (Pubitemid 16192338)
90. Sandbulte MR, Jimenez GS, Boon AC et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4(2), e59 (2007). (Pubitemid 46354439)
91. Abe T, Hemmi H, Miyamoto H et al. Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. J. Virol. 79(5), 2847-2858 (2005). (Pubitemid 40270563)
92. Abe T, Takahashi H, Hamazaki H et al. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J. Immunol. 171(3), 1133-1139 (2003). (Pubitemid 36900040)
93. Gronowski AM, Hilbert DM, Sheehan KC, Garotta G, Schreiber RD. Baculovirus stimulates antiviral effects in mammalian cells. J. Virol. 73(12), 9944-9951 (1999).
94. Harrison RL, Jarvis DL. Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce 'mammalianized' recombinant glycoproteins. Adv. Virus Res. 68, 159-191 (2006).
95. Kuroda K, Geyer H, Geyer R, Doerfler W, Klenk HD. The oligosaccharides of influenza virus hemagglutinin expressed in insect cells by a baculovirus vector. Virology 174(2), 418-429 (1990). • Joel R Haynes LigoCyte Pharmaceuticals, Inc., 2155 Analysis Drive, Bozeman, MT 59718, USA joel.haynes@ligocyte.com (Pubitemid 20060145)